Brian E. Lacy, PhD, MD (Chair)

Brian E. Lacy, Ph.D., M.D., is currently Professor of Medicine at the Geisel School of Medicine at Dartmouth, Section Chief of the Division of Gastroenterology & Hepatology, Director of the GI Motility Laboratory at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire and Director of the MD-PhD program at the Geisel School of Medicine at Dartmouth.

Dr. Lacy's clinical and basic science research interests focus on disorders of gastrointestinal motility, with an emphasis on irritable bowel syndrome, dyspepsia, gastroparesis, acid reflux disease, constipation, intestinal pseudo-obstruction, achalasia and visceral pain. He is the author or co-author of over 125 peer-reviewed articles and the author or co-author of numerous textbook chapters on gastrointestinal motility disorders and functional bowel disorders. Dr. Lacy is a reviewer for a number of scientific journals, and is a member of the American College of Gastroenterology, the American Gastroenterology Association, and the American Motility Society. He is co-chairman of the Rome Committee for Functional Bowel Disorders. Dr. Lacy is the co-author of a book for the general public on acid reflux disease, Healing Heartburn, is the author of Making Sense of IBS, a book for the general public on irritable bowel syndrome, and is the editor and author of 2 books for health care providers entitled Curbside Consultations in IBS: 49 Clinical Questions and Functional and Motility Disorders of the Gastrointestinal Tract. Dr. Lacy is the former Editor in Chief of the journal Clinical and Translational Gastroenterology. He is currently the Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Lacy received his doctorate in cell biology from Georgetown University in Washington, DC, and his medical degree from the University of Maryland in Baltimore. Dr. Lacy was a resident in Internal Medicine at the Dartmouth-Hitchcock Medical Center in Lebanon, NH, where he continued his training as Chief Resident and then as a Fellow in Gastroenterology. He is board certified in Gastroenterology.

Speaker Disclosures

Grant/Research Support: NIH, Takeda

Advisory Board Membership: Allergan, Ironwood Pharmaceuticals, Salix Pharmaceuticals.

Editorial Board Involvement: American Journal of Gastroenterology.

Darren M. Brenner, MD, AGAF

Darren M. Brenner, MD, is an associate professor of medicine and surgery at the Northwestern University Feinberg School of Medicine. He currently serves as director of the Gastrointestinal Physiology Laboratory and the Functional Bowel Center and as co-director of the Integrated Bowel Dysfunction Program. Dr. Brenner received his undergraduate degree from Washington University in St. Louis, his medical school training at the University of Chicago, and completed his residency and fellowship at the University of Michigan.

His clinical and research pursuits focus predominantly on functional and motility disorders. He is actively collaborating both nationally and internationally on studies in these areas. Dr. Brenner has also published extensively on these topics, and serves as a reviewer and associate editor for multiple GI peer-reviewed journals, including the American Journal of Gastroenterology, and has lectured regionally, nationally, and internationally on functional bowel disorders. He is a charter board member of the American Gastroenterological Association Academy of GI and Liver Educators, and also serves on the education, maintenance of certification, and publications committees of the American College of Gastroenterology. He is a fellow of the American Gastroenterological Association.

Speaker Disclosures

Grant/Research Support: Astra Zeneca

Consultant/Speaker Bureau:  Allergan, Astra Zeneca, Commonwealth Labs, Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, P&G, QOL Medical.

Advisory Board Membership:  Allergan, AstraZeneca, Commonwealth Labs, Ironwood Pharmaceuticals, Salix Pharmaceuticals, Synergy, P&G, QOL Medical.

Editorial Board Involvement: American Journal of Gastroenterology (Associate Editor).

Brooks D. Cash, MD, FACG

Brooks D. Cash, MD, is a professor of internal medicine at the University of South Alabama (USA), in Mobile, Alabama, where he has held a faculty position since 2013 and currently serves as chief of the Gastroenterology Division and director of the Motility and Physiology Service at the USA Digestive Health Center. Dr. Cash formerly served in the United States Navy for 24 years, retiring in 2013 as deputy commander for medicine at Walter Reed National Military Medical Center at the rank of captain. He also continues to serve as a professor of medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

Dr. Cash received his undergraduate degree with honors in business administration (finance) from the University of Texas at Austin. He earned his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his internship, residency, and gastroenterology fellowship at the National Naval Medical Center.

Dr. Cash is a diplomate of the American Board of Gastroenterology and a fellow of the American College of Physicians, the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. He has served as chair for numerous professional society committees as well as course director for national and regional ACG postgraduate meetings. Dr. Cash has served on the Rome Committee for Functional Gastrointestinal Disorders and has authored multiple articles and book chapters on a wide variety of gastrointestinal topics, including IBS and chronic constipation, colorectal cancer screening, CT colonography, acid peptic disorders, Barrett's esophagus, medical education techniques, and evidence-based medicine. He serves as associate editor for the American Journal of Gastroenterology, and is an editorial board member and reviewer for multiple internal medicine and gastroenterology medical journals. He is the 2016 recipient of the William Carey Award from the American College of Gastroenterology.

Speaker Disclosures

Consultant/Speaker's Bureau: Allergan, AstraZeneca, IMHealthScience, Sebela, Salix Pharmaceuticals, Takeda Pharmaceutical Company Limited, Torax.

Advisory Board Membership: Allergan, AstraZeneca, Salix Pharmaceuticals, Synergy, Takeda Pharmaceuticals U.S.A., Inc., Torax.

Editorial Board Involvement: American Journal of Gastroenterology

Philip S. Schoenfeld, MD, MSEd, MSc (Epi)

Philip S. Schoenfeld, MD, is a professor of medicine and director of the training program in GI epidemiology at the University of Michigan School of Medicine in Ann Arbor. He is an expert in the management of irritable bowel syndrome (IBS), chronic constipation, gastroparesis, and pelvic floor disorders, and he sees patients at the University of Michigan Functional Bowel Disorders Clinic.

Dr. Schoenfeld completed his medical degree and his master's degree in medical education at the University of Pennsylvania and his master's degree in clinical epidemiology at McMaster University in Hamilton, Ontario.

His research, which is funded by the National Institutes of Health and the US Department of Veterans Affairs, focuses on the treatment of IBS and chronic constipation, the application of evidence-based medicine to the management of gastrointestinal disorders, and the optimization of colon cancer screening with colonoscopy.

Dr. Schoenfeld is the former editor of the Selected Summaries section of the journal Gastroenterology and the former associate editor (Colon section) of the American Journal of Gastroenterology, and has served on the editorial boards of the Journal of Clinical Gastroenterology, Alimentary Pharmacology and Therapeutics, and Gastroenterology and Hepatology. He is a co-author of the American Journal of Gastroenterology supplement "An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome" (2002) and its second edition (2009), the American Journal of Gastroenterology supplement "An Evidence-Based Position Statement on the Management of Chronic Constipation in North America" (2005), the American College of Gastroenterology Guidelines for Colorectal Cancer Screening (2008), and the American Society for Gastrointestinal Endoscopy/American College of Gastroenterology's "Position Statement on Quality Indicators in the Performance of Colonoscopy" (in press).

Speaker Disclosures

Advisory Board: Actavis, AstraZeneca, Daiichi Sankyo Company, Limited, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Valeant Pharmaceuticals North America LLC